Last reviewed · How we verify
Cefotaxime Injection
At a glance
| Generic name | Cefotaxime Injection |
|---|---|
| Sponsor | Centre Hospitalier Universitaire de Besancon |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Precision Antibiotic Dosing for Appendectomy (PHASE1)
- Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP (PHASE4)
- PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury (PHASE3)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia (PHASE2)
- Paramedic Initiated Treatment of Sepsis Targeting Out-of-hospital Patients (PITSTOP) (PHASE4)
- Efficacy of an Adapted Antibiotherapy in Hurley Stage 2 Hidradenitis Suppurativa Patients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cefotaxime Injection CI brief — competitive landscape report
- Cefotaxime Injection updates RSS · CI watch RSS
- Centre Hospitalier Universitaire de Besancon portfolio CI